Switch theme
Sign up to access all valuation multiples
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
1997
64
LTM Revenue n/a
LTM EBITDA n/a
$457M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Elite Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Elite Pharmaceuticals achieved revenue of $56.6M and an EBITDA of $2.5M.
Elite Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Elite Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $34.2M | $56.6M | XXX | XXX | XXX |
| Gross Profit | $14.8M | $16.6M | XXX | XXX | XXX |
| Gross Margin | 43% | 29% | XXX | XXX | XXX |
| EBITDA | $6.4M | $2.5M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 4% | XXX | XXX | XXX |
| Net Profit | $8.9M | $3.6M | XXX | XXX | XXX |
| Net Margin | 26% | 6% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Elite Pharmaceuticals's stock price is $0.
Elite Pharmaceuticals has current market cap of $454M, and EV of $457M.
See Elite Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $457M | $454M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Elite Pharmaceuticals has market cap of $454M and EV of $457M.
Elite Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Elite Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Elite Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $457M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpElite Pharmaceuticals's NTM/LTM revenue growth is n/a
Elite Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Elite Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Elite Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Elite Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 66% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -61% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 27% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elite Pharmaceuticals acquired XXX companies to date.
Last acquisition by Elite Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Elite Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Elite Pharmaceuticals founded? | Elite Pharmaceuticals was founded in 1997. |
| Where is Elite Pharmaceuticals headquartered? | Elite Pharmaceuticals is headquartered in United States of America. |
| How many employees does Elite Pharmaceuticals have? | As of today, Elite Pharmaceuticals has 64 employees. |
| Is Elite Pharmaceuticals publicy listed? | Yes, Elite Pharmaceuticals is a public company listed on PINX. |
| What is the stock symbol of Elite Pharmaceuticals? | Elite Pharmaceuticals trades under ELTP ticker. |
| When did Elite Pharmaceuticals go public? | Elite Pharmaceuticals went public in 2009. |
| Who are competitors of Elite Pharmaceuticals? | Similar companies to Elite Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Elite Pharmaceuticals? | Elite Pharmaceuticals's current market cap is $454M |
| What is the current revenue growth of Elite Pharmaceuticals? | Elite Pharmaceuticals revenue growth between 2023 and 2024 was 66%. |
| Is Elite Pharmaceuticals profitable? | Yes, Elite Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
